Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
AssigneeVegenics Pty Limited
InventorsKari Alitalo, Taija Makinen
Life of this patent
Estimating the term…
Abstract
The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.
Claims56
A fusion protein comprising:
- (a) a polypeptide comprising a portion of a human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) extracellular domain (EC),
- wherein said portion consists essentially of the first, second, and third immunoglobulin-like domains of the VEGFR-3-EC, and
- (b) an immunoglobulin-like domain of human VEGFR-2 or an immunoglobulin Fc peptide,
- wherein (a) is fused to (b);
- and
- wherein said fusion protein binds to VEGFR-3 ligands VEGF-C and VEGF-D.
A fusion protein comprising:
- (a) a polypeptide comprising a portion of a human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) extracellular domain (EC);
- wherein said portion and said polypeptide bind to VEGFR-3 ligands VEGF-C and VEGF-D and comprise at least the first, second, and third immunoglobulin-like domains of the VEGFR-3-EC,
- wherein the polypeptide lacks VEGFR-3-EC immunoglobulin-like domains IV-VII;
- and
- (b) an immunoglobulin-like domain of human VEGFR-2 or an immunoglobulin Fc peptide,
- wherein (a) is fused to (b), and
- wherein the fusion protein binds VEGF-C and VEGF-D, is soluble, and lacks any transmembrane domain.
A polypeptide consisting essentially of:
- (i) a fragment of human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) consisting essentially of the first through third immunoglobulin-like domains of human VEGFR-3 extracellular domain (EC), and
- (ii) an immunoglobulin Fc peptide,
- wherein (i) is fused to (ii), and
- wherein the polypeptide binds both VEGF-C and VEGF-D.
A chimeric polypeptide comprising a fragment of a human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) extracellular domain (EC) fused to a heterologous polypeptide;
- wherein said fragment binds to VEGF-C and VEGF-D and comprises at least the first through third immunoglobulin-like domains of the VEGFR-3-EC,
- wherein the polypeptide lacks VEGFR-3-EC immunoglobulin-like domains IV-VII;
- and
- wherein the polypeptide is a soluble polypeptide lacking any transmembrane domain.
A method of treating a neoplastic disorder comprising administering to a mammalian subject having a neoplastic disorder a composition comprising a polypeptide, in an amount effective to inhibit neoplastic cell growth,
- wherein the polypeptide comprises a portion of a human Vascular Endothelial Growth Factor Receptor-3 (VEGFR-3) extracellular domain (EC);
- wherein said portion and said polypeptide bind to VEGFR-3 ligands VEGF-C and VEGF-D and comprise at least the first, second, and third immunoglobulin-like domains of the VEGFR-3-EC,
- wherein the polypeptide lacks VEGFR-3-EC immunoglobulin-like domains IV-VII;
- and
- wherein the polypeptide is a soluble polypeptide lacking any transmembrane domain.
Dependencies are inferred from the claim text.